2. Disease Areas
  3. Cancer Urogenital Disease
  4. Cervical Cancer Urogenital Cancer
  5. HPV-Positive Cervical Cancer

HPV-Positive Cervical Cancer

HPV-positive cervical cancer is primarily driven by high-risk human papillomavirus (HPV) infection, with the viral genome encoding early (E) genes E6 and E7 as key oncogenic drivers. These proteins inactivate tumor suppressor proteins p53 and Rb, respectively, promoting cellular immortalization and malignant transformation. The integration of HPV DNA into the host genome, commonly disrupting the E2 gene—a negative regulator of E6/E7—leads to uncontrolled expression of these oncogenes and progression to cancer. However, some cases occur without integration, maintaining episomal HPV DNA with intact E2, which correlates with better prognosis. The L1 gene, encoding the major capsid protein, is crucial for vaccine-induced immunity and serves as a target for prophylactic vaccines like Gardasil and Cervarix. Emerging research highlights the prognostic and predictive value of methylation status in L1 and E2 genes: high methylation of HPV16 L1 and E2 is associated with improved response to antiviral therapy with cidofovir, while low or absent methylation predicts better response to immune stimulation via TLR7 agonist imiquimod, underscoring the potential of epigenetic markers in guiding personalized treatment strategies.

HPV-Positive Cervical Cancer (3):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-146244
    Agatolimod 525625-52-9 98.84%
    Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC50 of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis.
    Agatolimod
  • HY-N12257
    Antimycin A2 27220-57-1 99.0%
    Antimycin A2 is a selective inhibitor of the cytochrome b-c1 complex in the mitochondrial electron transport chain. Antimycin A2 disrupts mitochondrial membrane potential and produces reactive oxygen species (ROS) by inhibiting electron transfer between cytochrome b and c. Antimycin A2 has bactericidal and piscicidal activity, as well as tumor cell growth inhibitory effects, and can induce S-phase cell cycle arrest and apoptosis in HeLa cells. Antimycin A2 is suitable for research of cervical cancer and fisheries management. Antimycin A2 can be naturally isolated from the fermentation products of Streptomyces sp. strains.
    Antimycin A2
  • HY-W489121
    YTK-105 774192-20-0
    YTK-105 is a p62/ZZ binding domain ligand and Autophagy enhancer. YTK-105 activates p62-dependent selective macroautophagy. YTK-105 serves as an autophagy-targeting ligand (ATL) for synthesizing AUTOTAC degraders.
    YTK-105